Navidea Biopharmaceuticals Inc. (NAVB)

0.17
AMEX : Health Technology
Prev Close 0.17
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.10 / 0.42
Avg Volume 584.60K
Exchange AMEX
Shares Outstanding 181.89M
Market Cap 27.34M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Navidea Biopharmaceuticals Announces Patent Extension For Lymphoseek®

Navidea Biopharmaceuticals Announces Patent Extension For Lymphoseek®

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 23, 2018 the U.

Navidea Biopharmaceuticals Appoints Adam Cutler To Board Of Directors

Navidea Biopharmaceuticals Appoints Adam Cutler To Board Of Directors

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company's board of...

Navidea Biopharmaceuticals Appoints Dr. Michael Rosol As Chief Medical Officer

Navidea Biopharmaceuticals Appoints Dr. Michael Rosol As Chief Medical Officer

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michael Rosol, PhD as Chief Medical...

Navidea Biopharmaceuticals To Present At The 11th Annual LD Micro Event 2018

Navidea Biopharmaceuticals To Present At The 11th Annual LD Micro Event 2018

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will...

Navidea Biopharmaceuticals Announces Presentation At The Radiological Society Of North America (RSNA) 104th Scientific Assembly And Annual Meeting 2018

Navidea Biopharmaceuticals Announces Presentation At The Radiological Society Of North America (RSNA) 104th Scientific Assembly And Annual Meeting 2018

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Dr.

Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan To Board Of Directors

Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan To Board Of Directors

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Kathy Rouan, PhD, to the Company's...

Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter of 2018.

Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, November 7...

Navidea Biopharmaceuticals Wins Dismissal Of Platinum Litigation

Navidea Biopharmaceuticals Wins Dismissal Of Platinum Litigation

On October 31, 2018, Judge Valerie Caproni of the United States District Court for the Southern District of New York entered an Opinion and Order, as well as a Judgment, dismissing all claims raised by Platinum-Montaur Life Sciences LLC...

Navidea Biopharmaceuticals Receives Acceptance Letter From NYSE American

Navidea Biopharmaceuticals Receives Acceptance Letter From NYSE American

As previously disclosed, on August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification...

Navidea Biopharmaceuticals To Present Data On The Manocept Platform At 2018 ACR Annual Meeting

Navidea Biopharmaceuticals To Present Data On The Manocept Platform At 2018 ACR Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will present a poster detailing results from...

Navidea Biopharmaceuticals To Present At The 2018 BIO Investor Forum

Navidea Biopharmaceuticals To Present At The 2018 BIO Investor Forum

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that its Chief Executive Officer, Jed Latkin, will...

Navidea Biopharmaceuticals Announces Acceptance Into The National Institutes Of Health Commercialization Accelerator Program

Navidea Biopharmaceuticals Announces Acceptance Into The National Institutes Of Health Commercialization Accelerator Program

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today acceptance into the National Institutes of Health...

Navidea Biopharmaceuticals Announces Closing Of A $3 Million Private Placement

Navidea Biopharmaceuticals Announces Closing Of A $3 Million Private Placement

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today closing of a $3 million private placement.

Navidea Biopharmaceuticals Announces Results Of The Annual Shareholder Meeting

Navidea Biopharmaceuticals Announces Results Of The Annual Shareholder Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced preliminary results of matters voted upon during the...

Navidea Biopharmaceuticals Announces Details Of 2018 Annual General Meeting

Navidea Biopharmaceuticals Announces Details Of 2018 Annual General Meeting

As previously announced, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, will host a conference call today, August 16,...

Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American

Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American

On August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a letter from NYSE American LLC ("NYSE...

Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results

Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter of 2018.

Navidea Management To Host Moderated Q&A Webcast To Provide Corporate Update

Navidea Management To Host Moderated Q&A Webcast To Provide Corporate Update

Navidea Biopharmaceuticals (NYSE American: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session...

Navidea To Host Moderated Q&A Webcast With Management

Navidea To Host Moderated Q&A Webcast With Management

Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session focused on...

Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results

Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2018.

Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Wednesday, May 9, 2018 at...

Navidea Biopharmaceuticals Schedules Conference Call To Discuss Future Outlook And Outcomes Of Court Trial

Navidea Biopharmaceuticals Schedules Conference Call To Discuss Future Outlook And Outcomes Of Court Trial

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call...

Navidea Biopharmaceuticals To Present At 25th Annual Future Leaders In The Biotech Industry

Navidea Biopharmaceuticals To Present At 25th Annual Future Leaders In The Biotech Industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at...

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Navidea Biopharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results...

Navidea Biopharmaceuticals Schedules Fourth Quarter And Full Year 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals Schedules Fourth Quarter And Full Year 2017 Earnings Conference Call And Business Update

Navidea Biopharmaceuticals (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call...

Navidea To Host Moderated Q&A Webcast With Management

Navidea To Host Moderated Q&A Webcast With Management

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer...

TheStreet Quant Rating: D- (Sell)